Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06968442

The Role of Obesity in Severe COVID-19 Pathophysiology

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths worldwide. As of 2024, the SARS-CoV-2 Omicron variant is the predominant strain circulating within the population, generally causing mild upper respiratory tract infections. However, hospitalizations and case fatalities due to COVID-19 continue, and there is a high probability that a new human coronavirus will emerge in the future. Understanding the pathophysiology of severe COVID-19 remains highly relevant, as its mechanisms may be comparable to those of other respiratory viral infections.

SARS-CoV-2 infects human cells primarily by binding to angiotensin-converting enzyme 2 (ACE2) and type 2 transmembrane serine protease (TMPRSS2) receptors, which are both expressed in alveolar epithelial type II cells, through the virus' spike protein. In a later stage, the replication of SARS-CoV-2 and activation of resident immune cells lead to the infiltration and activation of large numbers of innate immune cells. Consequently, this results in an excessive pro-inflammatory immune response, including increased production of IL-6, a hallmark cytokine of severe COVID-19. Eventually, the excessive inflammation results in microthrombus formation and pulmonary edema.

Further studies have indicated that SARS-CoV-2 spike-specific antibodies, along with alveolar macrophages, play a pivotal role in the pathophysiology of severe COVID-19. Alveolar macrophages, which reside in the lung alveoli, are typically the first immune cells to sense pulmonary pathogens. However, these cells can also bind IgG antibodies through their Fc-receptor, leading to cellular activation. When stimulated with both a viral stimulus and anti-SARS-CoV-2 IgG antibodies from severe COVID-19 patients (a situation similar to that in the lungs of these patients) alveolar macrophages elicit a significant proinflammatory response. This response aligns with the observed post-seral conversion deterioration in COVID-19 patients.

Obesity is a significant risk factor for developing severe COVID-19, but the underlying mechanism is not well understood. Previous studies report that macrophages in obese patients are skewed towards a pro-inflammatory phenotype due to altered fatty acid contents, particularly increased saturated fatty acids. Using our in vitro obesity model, which incorporates higher saturated fatty acid contents, the investigators already demonstrated that SARS-CoV-2 antibody-mediated inflammation of alveolar macrophages is increased (unpublished data). Thus, this may explain why obese patients are more likely to develop severe COVID-19.

To validate these in vitro findings, the investigators aim to confirm these results in monocyte-derived macrophages isolated from individuals with and without obesity. Additionally, the investigators will investigate the underlying mechanisms involved in detail. This study will provide valuable insights into the role of obesity in severe COVID-19 and potentially inform therapeutic strategies for at-risk populations.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

COVID-19 Antibody COVID-19 Body Weight Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Signs and Symptoms Virus Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Franciscus

Rotterdam, South Holland, 3045PM, Netherlands

Location status: Recruiting

Location contact

David S.Y. Ong, M.D., Ph.D., Pharm.D., M.Sc.

PRINCIPAL_INVESTIGATOR

About this study

This is a mono-center, prospective cohort study involving both a test group and a control group. The test group comprises patients with obesity eligible for bariatric surgery at Franciscus Hospital, while the control group consists of age- (maximum 5-year difference) and sex-matched non-obese healthcare workers at Franciscus Hospital. Blood samples will be collected from all participants at a single time point.

Obese patients will be approached for informed consent during their intake appointments, typically weeks to months before their bariatric surgery. Blood samples will be collected before surgery or during surgery to minimize any potential adverse effects. Collaborating researchers from the surgery department will manage the inclusion of obese patients and coordinate their blood collection.

For the non-obese control group, investigators from MMI will manage participant inclusion and blood sample collection.

Participants from Franciscus Hospital with obesity (Cohort 1) and healthcare workers without obesity (Cohort 2) will undergo a single venipuncture after an 8-hour fasting period. A total of 40 mL of blood will be collected in four 10 mL EDTA tubes.

At the Medical Microbiology and Infection Control (MMI) laboratory of Franciscus, blood samples will be collected after which these are sent to the Center for Infection and Molecular Medicine (CIMM) laboratory in Amsterdam UMC. Here, blood will be processed (i.e., isolation of plasma, monocytes, and remaining peripheral blood mononuclear cells (PBMCs)), where after monocytes will be put into culture to become monocyte-derived macrophages. Macrophage stimulations and additional macrophage analyses will be performed at Amsterdam UMC. Data obtained from analyses in Amsterdam UMC will be further analyzed in Amsterdam UMC by coordinating investigator Ashwin Mak (who is also affiliated at CIMM in Amsterdam UMC) and co-investigator Dr. Jeroen den Dunnen. Monocytes and plasma will be stored in Amsterdam UMC until the end of this study, where after the remaining materials will be transported to Franciscus.

Isolated PBMCs and plasma will be transported in the following days after isolation to Franciscus MMI for T cell stimulations and antibody analyses. In the analyses overview below, the location where each analysis will be performed is noted (i.e., MMI and CIMM). Coded samples and data will be stored at Amsterdam UMC until the end of this study, where after these samples are destroyed and data are deleted. MTA and DTA documents will be prepared for the transfer of blood and data to Amsterdam UMC.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Cohort 1 (obesity cohort)

  • ≥18 and ≤65 years of age
  • BMI ≥30 kg/m²
  • Patient of Franciscus Hospital

Cohort 2 (control cohort)

  • ≥18 and ≤65 years of age
  • BMI <25 kg/m²
  • Healthcare workers of Franciscus Hospital

Exclusion criteria

(for both cohorts):

  • Acute infection or current systemic immunological disorders
  • Use of immune-modulatory medication (i.e., corticosteroids and biologicals)
  • Hormonal therapy

Treatment and study plan

Venipuncture

Procedure

Simple blood collection

Other names: Venapuncture, Blood collection

Primary outcomes

  1. The concentration of pro-inflammatory cytokines (IL-6, IL-1β, and TNF) produced by macrophages upon both SARS-CoV-2 viral and antibody costimulation.

    Time frame: Baseline

    Monocytes will be isolated from blood of participants of both groups, whereafter these are differentiated into macrophages. These macrophages will be stimulated with a virus and SARS-CoV-2 IgG combined stimulation. After the stimulation, the concentration of pro-inflammatory cytokines is measured in the supernatant of the macrophages.

Secondary outcomes

  1. The concentration of pro-inflammatory cytokines (IL-6, IL-1β, and TNF) produced by macrophages upon separate viral stimulation or SARS-CoV-2 antibody stimulation

    Time frame: Baseline

    Monocytes will be isolated from blood of participants of both groups, whereafter these are differentiated into macrophages. These macrophages will be stimulated separately with a virus and SARS-CoV-2 IgG stimulation. After the stimulation, the concentration of pro-inflammatory cytokines is measured in the supernatant of the macrophages.

  2. The plasma concentration of pro-inflammatory cytokines

    Time frame: Baseline

    Pro-inflammatory cytokines will be directly measured in plasma.

  3. Measurement of other cytokines that are produced by macrophages upon viral stimulation, antibody stimulation, or both

    Time frame: Baseline

    Monocytes will be isolated from blood of participants of both groups, whereafter these are differentiated into macrophages. These macrophages will be stimulated with a viral stimulation, SARS-CoV-2 IgG stimulation or both combined. After the stimulations, the concentration of additional cytokines (IL-10, IFNg, IFNa, IFNb) will be measured in the supernatant of the macrophages.

  4. Expression levels of Fc receptors on the surface of macrophages

    Time frame: Baseline

    Macrophages will be analyzed by flow cytometry to determine the expression levels of Fc receptors (including CD16, CD32a, CD32b, CD64).

  5. The level of intracellular lipids in monocytes

    Time frame: Baseline

    Monocytes isolated from blood will be analyzed by flow cytometry to assess the intracellular lipid content

  6. Gene expression levels of proteins related to immune signalling or metabolic pathways

    Time frame: Baseline

    Molecular techniques will be applied to assess the gene expression levels of interesting proteins involved in immune signalling or metabolic pathways.

  7. Chromatin accessibility, measured as the number of 'reads per genomic region' of genes related to Fc-receptor activation in macrophages

    Time frame: Baseline

    ATAC-seq will be applied to determine the chromatine accessibility of genes related to Fc-receptor (i.e., receptors binding the Fc-part of antibodies) activation in macrophages. These include genes encoding for the receptors itself, as well as genes encoding for proteins related with the related intracellular signalling pathways upon Fc-receptor activation. The measured unit will be the number of reads per genomc region.

  8. The level of lactate production by macrophages upon stimulation with anti-SARS-CoV-2 IgG.

    Time frame: Baseline

    Lactate is the final product of the glycolysis metabolic pathway. The level of lactate produced by macrophages, thus resembling glycolysis activity, will be assessed after stimulaten with anti-SARS-CoV-2 IgG. The concentration will be measured in mM.

  9. The concentration of proteins in plasma

    Time frame: Baseline

    Using a proteomics approach, the concentration of over 1000 proteins will be assessed in plasma.

  10. The level of SARS-CoV-2 specific T cell responses and plasma antibodies

    Time frame: Baseline

    To determine the adaptive immunity against SARS-CoV-2, T cell responses and antibodies specific to SARS-CoV-2 proteins Spike, Spike S2, Spike S2, and Nucleocapsid will be assessed

Study contacts

Contact information is provided by the study sponsor or research team.

Willem A Mak, M.Sc.

CONTACT

[email protected]

+316 40897778

Sponsors and collaborators

Lead sponsor

Franciscus Gasthuis

Other

Registry information

Official study title

SARS-CoV-2 Antibody-mediated Inflammatory Responses by Macrophages in Individuals With and Without Obesity

Acronym: SAMO

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
May 13, 2025
Registry last updated
May 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.